# US 2012/0252767 A1 · Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252767 A1
- Document ID: US20120252767A1
- Status: Published application
- Kind: A1
- Application number: 13/492,138
- Filed: 2012-06-08
- Published: 2012-10-04
- Earliest claimed: 2004-10-07
- Assignees: Teva Women's Health, Inc.
- Inventors: Charles E. Diliberti; Kathleen Z. Reape; Lance J. Bronnenkant
- Web page: https://patentgrep.com/patent/US20120252767A1

## CPC

- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 15/18: Feminine contraceptives
- A61P 17/10: Anti-acne agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.

## Claims

### Claim at position 1

-135. (canceled)

### Claim 136

A method of contraception, the method comprising:
administering to a female in need thereof a dosage comprising estrogen and progestin for a period of 83 to 89 consecutive days,
wherein the dosage comprising estrogen and progestin is administered in at least three phases,
wherein the daily dosage of estrogen in the first phase is equivalent to 15 μg to 25 μg of ethinyl estradiol, the daily dosage of estrogen in the second phase is equivalent to 20 μg to 30 μg of ethinyl estradiol, and the daily dosage of estrogen in the third phase is equivalent to 25 μg to 35 μg of ethinyl estradiol,
wherein the total daily dosage of estrogen and progestin in the second phase is higher than the total daily dosage of estrogen and progestin in the first phase, and
wherein the total daily dosage of estrogen and progestin in the third phase is higher than the total daily dosage of estrogen and progestin in the second phase.

### Claim 137 (depends on 136)

The method of claim 136, wherein the daily dosage of progestin in each of the three phases is equivalent to 100 μg to 150 μg of levonorgestrel.

### Claim 138 (depends on 136)

The method of claim 136, wherein the progestin is selected from the group consisting of levonorgestrel, norethindrone, norethindrone acetate, desogestrel, gestodene, dienogest, norgestimate, cyproterone acetate, norelgestromin, etonogestrel, progesterone, ethynodiol diacetate, norgestrel, trimegestone, medroxyprogesterone acetate, chlormadinone acetate, drospirenone, and esters, conjugates, and prodrugs thereof.

### Claim 139 (depends on 136)

The method of claim 136, wherein the estrogen is selected from the group consisting of ethinyl estradiol, estradiol, estradiol acetate, estradiol valerate, mestranol, and esters, conjugates, and prodrugs thereof.

### Claim 140 (depends on 136)

The method of claim 136, further comprising administering to the female a daily dosage consisting essentially of estrogen for a period of 2 to 8 consecutive days following the administration of the dosage comprising estrogen and progestin for 83 to 89 consecutive days.

### Claim 141 (depends on 140)

The method of claim 140, wherein the daily dosage of estrogen that is administered for a period of 2 to 8 consecutive days is 5 μg to 30 μg of ethinyl estradiol.

### Claim 142 (depends on 140)

The method of claim 140, further comprising administering an additional active agent that is administered (i) in combination with the dosage consisting essentially of estrogen for a period of 2 to 8 consecutive days following the administration of the dosage comprising estrogen and progestin for 83 to 89 consecutive days, (i continuously, (iii) intermittently, (iv) one time, or (v) once weekly.

### Claim 143 (depends on 136)

The method of claim 136, wherein the female is also treated for acne, headache or pelvic pain.

### Claim 144 (depends on 136)

The method of claim 136, wherein the first phase is 35 to 49 days, the second phase is 14 to 28 days, and the third phase is 14 to 32 days.

### Claim 145 (depends on 144)

The method of claim 144, wherein the first phase is 42 days, the second phase is 21 days, and the third phase is 21 days.

### Claim 146 (depends on 145)

The method of claim 145,
wherein the daily dosage of estrogen in the first phase is 20 μg of ethinyl estradiol, the daily dosage of estrogen in the second phase is 25 μg of ethinyl estradiol, and the daily dosage of estrogen in the third phase is 30 μg of ethinyl estradiol, and
wherein the daily dosage of progestin in each of the three phases is 150 μg of levonorgestrel.

### Claim 147 (depends on 146)

The method of claim 146, further comprising administering to the female a daily dosage consisting essentially of 10 μg of ethinyl estradiol for 7 consecutive days following the administration of the dosage comprising estrogen and progestin.

### Claim 148 (depends on 136)

The method of claim 136, wherein the first phase is 14 to 28 days, the second phase is 35 to 49 days, and the third phase is 14 to 32 days,

### Claim 149 (depends on 148)

The method of claim 148, wherein the first phase is 21 days, the second phase is 42 days, and the third phase is 21 days.

### Claim 150 (depends on 149)

The method of claim 149,
wherein the daily dosage of estrogen in the first phase is 20 μg of ethinyl estradiol, the daily dosage of estrogen in the second phase is 25 μg of ethinyl estradiol, and the daily dosage of estrogen in the third phase is 30 μg of ethinyl estradiol, and
wherein the daily dosage of progestin in each of the three phases is 150 μg of levonorgestrel.

### Claim 151 (depends on 150)

The method of claim 150, further comprising administering to the female a daily dosage consisting essentially of 10 μg of ethinyl estradiol for 7 consecutive days following the administration of the dosage comprising estrogen and progestin.

### Claim 152 (depends on 136)

The method of claim 136, wherein the first phase is 14 to 28 days, the second phase is 14 to 28 days, and the third phase is 35 to 53 days.

### Claim 153 (depends on 152)

The method of claim 152, wherein the first phase is 21 days, the second phase is 21 days, and the third phase is 42 days.

### Claim 154 (depends on 153)

The method of claim 153,
wherein the daily dosage of estrogen in the first phase is 20 μg of ethinyl estradiol, the daily dosage of estrogen in the second phase is 25 μg of ethinyl estradiol, and the daily dosage of estrogen in the third phase is 30 μg of ethinyl estradiol, and
wherein the daily dosage of progestin in each of the three phases is 150 μg of levonorgestrel.

### Claim 155 (depends on 154)

The method of claim 154, further comprising administering to the female a daily dosage consisting essentially of 10 μg of ethinyl estradiol for 7 consecutive days following the administration of the dosage comprising estrogen and progestin.

### Claim 156

A method of contraception, the method comprising:
administering to a female in need thereof a dosage comprising estrogen and progestin for a period of greater than 30 consecutive days,
wherein the dosage comprising estrogen and progestin is administered in at least two phases,
wherein the daily dosage of estrogen in the first phase is equivalent to 15 μg to 25 μg of ethinyl estradiol,
the daily dosage of estrogen in the second phase is equivalent to 20 μg to 30 μg of ethinyl estradiol,
wherein the total daily dosage of estrogen and, progestin in a second phase is higher than the total daily dosage of estrogen and progestin in the first phase, and
wherein the daily dosage of progestin in the second phase is less than twice the daily dosage of progestin in the first phase.

### Claim 157 (depends on 156)

The method of claim 156, wherein the daily dosage of estrogen in the second phase is higher than a daily dosage of estrogen in the first phase.

### Claim 158 (depends on 156)

The method of claim 156, wherein the progestin is selected from the group consisting of levonorgestrel, norethindrone, norethindrone acetate, desogestrel, gestodene, dienogest, norgestimate, cyproterone acetate, norelgestromin, etonogestrel, progesterone, ethynodiol diacetate, norgestrel, trimegestone, medroxyprogesterone acetate, chlormadinone acetate, drospirenone, and esters, conjugates, and prodrugs thereof.

### Claim 159 (depends on 156)

The method of claim 156, wherein the estrogen is selected from the group consisting of ethinyl estradiol, estradiol, estradiol acetate, estradiol valerate, mestranol, and esters, conjugates, and prodrugs thereof.

### Claim 160 (depends on 156)

The method of claim 156, wherein the dosage comprising estrogen and progestin is administered for a period of 31 to 190 consecutive days.

### Claim 161 (depends on 160)

The method of claim 160, wherein each phase is 7 to 84 days.

### Claim 162 (depends on 156)

The method of claim 156, further comprising administering a daily dosage consisting essentially of estrogen for a period of 2 to 8 consecutive days.

### Claim 163 (depends on 162)

The method of claim 162, wherein the dosage of estrogen that is administered for the period of 2 to 8 consecutive days is 5 μg to 30 μg of ethinyl estradiol.

### Claim 164 (depends on 162)

The method of claim 162, wherein the dosage of estrogen that is administered for the period of 2 to 8 consecutive days is 10 μg of ethinyl estradiol.

### Claim 165 (depends on 164)

The method of claim 164, further comprising administering an additional active agent that is administered (i) in combination with a dosage consisting essentially of an estrogen for a period of 2 to 8 consecutive days following the administration of the dosage comprising estrogen and progestin for a period of greater than 30 consecutive days, (ii) continuously, (iii) intermittently, (iv) one time, or (v) once weekly.
